MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia

    P. Svenningsson, P. Odin, N. Dizdar, F. Bergquist, A. Johansson, D. Nyholm, K. Wictorin, J. Tedroff (Uppsala, Sweden)

    Objective: The primary objective was to investigate the safety and tolerability of IRL752 in PD patients with dementia in a randomized controlled trial. Secondary outcome…
  • 2019 International Congress

    Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

    N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

    Objective: To test the efficacy of 3 drugs predicted by IBM Watson for Drug Discovery (WDD) as having the potential to treat L-DOPA-induced dyskinesia (LID).…
  • 2019 International Congress

    Exergame training in Early Onset Ataxia patients

    R. Brandsma, I. Ganzevoort, M. Berg, ZT. Dominguez Vega, LD. Jelsma, MM. Schoemaker, NM. Maurits, CJC. Lamoth, DA. Sival (Groningen, Netherlands)

    Objective: In ambulant EOA children, we aimed to study the effect of a medically designed “ice-skating exergame” on balance, posture and muscle force parameters Background:…
  • 2019 International Congress

    POLR3A-related spastic ataxia: new mutations and a look into the clinical and MRI phenotype

    J. Infante, KM. Serrano, E. Marco-de Lucas, A. Sánchez-Rodríguez, J. Berciano, M. Corral, X. Farré, A. Matilla (Santander, Spain)

    Objective: To report the clinical, molecular and magnetic resonance imaging features of eight patients with POLR3A-realted spastic ataxia. Background: POLR3-related disorders comprise a number of…
  • 2019 International Congress

    Prospective study of cognition in SCA2

    T. Monte, E. Reckziegel, M. Augustin, O. Barsottini, JL. Pedroso, F. Vargas, ML. Saraiva-Pereira, V. Leotti, L. Jardim (Porto Alegre, Brazil)

    Objective: Evaluate prospectively cognitive dysfunction in subjects with SCA2 using Mini Mental Examination (MMSE) and Montreal Cognition Assesment (MOCA), looking for correlation between cognitiion and motor…
  • 2019 International Congress

    Research on the modifier gene of Hereditary spinocerebellar ataxia type 2

    JLW. Wang, ZL. Liu (Changsha, China)

    Objective: To investigate the influence of CAG trinucleotides repeat of some (CAG)n-containing gene and some gene polymorphisms in AO of SCA2, and analyse the difference…
  • 2019 International Congress

    Convalescent Chorea in West Nile Virus Encephalitis

    A. Kirby, M. Afshari (Chicago, IL, USA)

    Objective: To discuss an unusual case of chorea in WNV encephalitis. Background: The "neuroinvasive" form of human infection with West Nile virus (WNV) is known…
  • 2019 International Congress

    Isolated unilateral tensor veli palatini myoclonus causing objective tinnitus without palatal elevation

    C. Selvadurai, S. Schaefer (New Haven, CT, USA)

    Objective: To describe a case of unilateral ear clicking caused by isolated tensor veli palatini myoclonus without palatal elevation. Background: Palatal myoclonus may be secondary…
  • 2019 International Congress

    Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: Roles of Nrf2-ARE signaling pathway

    XF. Guo, T. Wang, J. Huang, N. Xiong, C. Han, K. Ma, Y. Xia, F. Wan, JJ. Hu, SJ. Yin, L. Kou, YD. Sun, JW. Wu (Wuhan, China)

    Objective: In this study, we tested whether hydralazine can attenuate 1-Methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced neurotoxicity in vitro and in vivo by activating Nrf2…
  • 2019 International Congress

    Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

    M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)

    Objective: To investigate the effects of safinamide (saf) on synaptic plasticity of spiny projection neurons (SPNs) and the antiparkinsonian effect in dopamine (DA) denervated rats…
  • « Previous Page
  • 1
  • …
  • 144
  • 145
  • 146
  • 147
  • 148
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley